Movatterモバイル変換


[0]ホーム

URL:


DE2253086C3 - Preserving solutions for infusion and for storage of tissues and tissue parts - Google Patents

Preserving solutions for infusion and for storage of tissues and tissue parts

Info

Publication number
DE2253086C3
DE2253086C3DE2253086ADE2253086ADE2253086C3DE 2253086 C3DE2253086 C3DE 2253086C3DE 2253086 ADE2253086 ADE 2253086ADE 2253086 ADE2253086 ADE 2253086ADE 2253086 C3DE2253086 C3DE 2253086C3
Authority
DE
Germany
Prior art keywords
tissues
storage
infusion
solutions
tissue parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2253086A
Other languages
German (de)
Other versions
DE2253086B2 (en
DE2253086A1 (en
Inventor
Martin Prof. Dr. 1000 Berlin Wenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to DE2253086ApriorityCriticalpatent/DE2253086C3/en
Publication of DE2253086A1publicationCriticalpatent/DE2253086A1/en
Publication of DE2253086B2publicationCriticalpatent/DE2253086B2/en
Application grantedgrantedCritical
Publication of DE2253086C3publicationCriticalpatent/DE2253086C3/en
Expiredlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Description

Translated fromGerman

Es ist bekannt, Lösungen für Körperinfusionen mit geeigneten Ionen und Nährstoffen zu versehen. Sokönnen derartige Lösungen im einfacheren Fall einen Gehalt von 0,9% NaCl besitzen; sie können aber aucheine Vielzahl von Ionen, Glukose, Serum-Eiweiß sowie weitere Blutbestandteile gelöst enthalten. ÄhnlicheLösungen verwendet man zur in-vitro-Behandlung von überlebendem Gewebe, z. B. für Zellkulturen oder zurKonservierung von vitalen Organen. In sämtlichen Fällen dient als Lösungsmittel für die zu lösenden Stoffenormales Wasser, manchmal mit geringen Anteilen von Glycerin.It is known to provide solutions for body infusions with suitable ions and nutrients. SoIn the simpler case, such solutions can contain 0.9% NaCl; but they can toocontain a large number of dissolved ions, glucose, serum protein and other blood components. SimilarSolutions are used for the in vitro treatment of surviving tissue, e.g. B. for cell cultures or forPreservation of vital organs. In all cases serves as a solvent for the substances to be dissolvednormal water, sometimes with small amounts of glycerine.

Es wurde nun gefunden, daß derartige Lösungen oder Medien biologische Objekte wie Zellen, Organe und denGesamtorganismus gegen Schädigungen besser konservieren, wenn dem üblichen Lösungsmittel Wasser (H2O)ein Anteil von 2—99,9% schweren Wassers (D2O) zugesetzt wird. Als besonders vorteilhafter Konzentrationsbereichuat sich ein Schwerwasser-Anteil von 7—25% erwiesen. Die Stabilisierung biologischerSysteme nimmt bis zu einem Schwerwasser-Anteil von 10—15% besonders stark zu. Eine weitere Erhöhungder Schwerwasserkonzentration führt zwar zu einer weiteren Erhöhung der biologischen Stabilisierung, derrelative Effekt ist aber geringer.It has now been found that such solutions or media preserve biological objects such as cells, organs and the entire organism better against damage if the usual solvent water (H2 O) contains 2-99.9% heavy water (D2 O). is added. A heavy water content of 7-25% has proven to be a particularly advantageous concentration range. The stabilization of biological systems increases particularly strongly up to a heavy water content of 10-15%. A further increase in the heavy water concentration leads to a further increase in biological stabilization, but the relative effect is less.

Manchmal wird man zweckmäßigerweise den Schwerwasser-Anteil im primären Medium so hochbemessen, daß die Schwerwasserkonzentration nach Verdünnung durch den Wasseranteil im Gewebe wieder7—25% beträgtSometimes the proportion of heavy water in the primary medium is expediently so highmeasured that the heavy water concentration after dilution by the water content in the tissue again7-25%

Die erfindungsgemäß D2O-haltigen Lösungen erlauben die Konservierung der nativen biologischenEigenschaften von Zellen und Organen über einen längeren Zeitraum als im entsprechenden H2O-Medium.Eine spezielle Anwendung ist das Durchströmen von Organen, die zu Transplantationszwecken konserviertwerden sollen. Dabei kann mit der erfindungsgemäßen Lösung, die noch zusätzlich Blutanteile gelöst oder inSuspension enthalten kann, den Organen zusätzlich Sauerstoff zugeführt werden.The D2O-containing solutions according to the invention allow the native biological solutions to be preservedProperties of cells and organs over a longer period of time than in the corresponding H2O medium.A special application is the perfusion of organs that have been preserved for transplantation purposesshould be. Here, with the solution according to the invention, which also dissolved or inCan contain suspension, the organs are additionally supplied with oxygen.

Eine weitere Anwendung ergibt sich bei der Konservierung von Seren, Blutkonserven und Enzymenund ähnlichem biologischem Material, das im Laufe der Zeit oder durch zu hohe oder zu tiefe Temperaturendenaturiert wird. Auch hierbei ist die Effektivität einer D2O-Konzentration im Bereich von 7—25% besondersausgeprägtAnother application is the preservation of serums, blood products and enzymesand similar biological material that changes over time or from temperatures that are too high or too lowis denatured. Here, too, the effectiveness of a D2O concentration in the range of 7-25% is specialpronounced

Die stabilisierenden Effekte von schwerem Wasser bei Erythrocyten beim Erwärmen bzw. beim Gefrierenund bei osmotischer Schädigung gehen aus folgenden Kurven hervor.The stabilizing effects of heavy water on erythrocytes when heated or when frozenand in the case of osmotic damage can be seen from the following curves.

6060

2020th

20 40 U K20 40 U K

Änderung des Schutzeffektes mit der D2O-Konzentrationbei Erythrocyten:Change in the protective effect with the D2 O concentration in erythrocytes:

Obere Kurve: Hämolyse durch Hyperthermie 55° C,40 min, 5%ige Zellsuspension mit 9 g/l NaCl,Upper curve: hemolysis by hyperthermia 55 ° C,40 min, 5% cell suspension with 9 g / l NaCl,

Mittlere Kurve: Hämolyse hypoosmotische Salz-Konzentration (3,8 g/l NaCl), 5%igeZellsuspension 20° C, 20 min,Middle curve: hemolysis hypoosmotic salt concentration (3.8 g / l NaCl), 5%Cell suspension 20 ° C, 20 min,

Untere Kurve: Hämolyse durch Gefrieren -196° C,12 h (Abkühlung -4,3°/min), 5%ige Zellsuspension
55
Lower curve: hemolysis by freezing -196 ° C, 12 h (cooling -4.3 ° / min), 5% cell suspension
55

Aus der Kurve ist ersichtlich, daß bei den drei geprüften Schädigungsarten der Schutzeffekt nichtlinear mit der Zunahme der D2O-Konzentration ansteigt, sondern daß bereits bei einer Konzentrationvon ca. 20% D2O 60—75% der maximalen Schutzwirkungerreicht wird.The curve shows that with the three types of damage tested, the protective effect does not increase linearly with the increase in the D2O concentration, but that 60-75% of the maximum protective effect is achievedat a concentration of approx. 20% D 2 O.

Claims (2)

Translated fromGerman
Patentansprüche:Patent claims:1. Konservierende Lösungen zu Infusionszwecken oder zur Aufbewahrung von Organen und Gewebensowie Gewebeteilen, Eiweißen oder Enzymen, dadurch gekennzeichnet, daß sie alsLösungsmittel schweres Wasser enthalten.1. Preserving solutions for infusion purposes or for the storage of organs and tissuesas well as tissue parts, proteins or enzymes, characterized in that they are asSolvents contain heavy water.2.Lösungen gemäß Anspruch 1, dadurch gekennzeichnet,daß sie einen Schwerwasseranteil von 7—25% enthalten.2. Solutions according to claim 1, characterized in that they contain a heavy water content of 7-25%.
DE2253086A1972-10-251972-10-25 Preserving solutions for infusion and for storage of tissues and tissue partsExpiredDE2253086C3 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
DE2253086ADE2253086C3 (en)1972-10-251972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
DE2253086ADE2253086C3 (en)1972-10-251972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Publications (3)

Publication NumberPublication Date
DE2253086A1 DE2253086A1 (en)1974-05-09
DE2253086B2 DE2253086B2 (en)1978-06-15
DE2253086C3true DE2253086C3 (en)1979-02-15

Family

ID=5860372

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DE2253086AExpiredDE2253086C3 (en)1972-10-251972-10-25 Preserving solutions for infusion and for storage of tissues and tissue parts

Country Status (1)

CountryLink
DE (1)DE2253086C3 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7662185B2 (en)1999-12-302010-02-16Osteotech, Inc.Intervertebral implants
US7726002B2 (en)2001-12-052010-06-01Osteotech, Inc.Processes for making spinal intervertebral implant, interconnections for such implant
US7780708B2 (en)2000-10-202010-08-24Osteotech, Inc.Implant retaining device
US8202539B2 (en)2007-10-192012-06-19Warsaw Orthopedic, Inc.Demineralized bone matrix compositions and methods
US8328876B2 (en)2003-12-312012-12-11Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US8333985B2 (en)2004-01-272012-12-18Warsaw Orthopedic, Inc.Non-glycerol stabilized bone graft
US8357384B2 (en)2007-06-152013-01-22Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US8372157B2 (en)2007-02-122013-02-12Warsaw Orthopedic, Inc.Joint revision implant
US8642061B2 (en)2007-06-152014-02-04Warsaw Orthopedic, Inc.Method of treating bone tissue
US8734525B2 (en)2003-12-312014-05-27Warsaw Orthopedic, Inc.Osteoinductive demineralized cancellous bone
US8911759B2 (en)2005-11-012014-12-16Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US9011537B2 (en)2009-02-122015-04-21Warsaw Orthopedic, Inc.Delivery system cartridge
US9333082B2 (en)2007-07-102016-05-10Warsaw Orthopedic, Inc.Delivery system attachment
US9554920B2 (en)2007-06-152017-01-31Warsaw Orthopedic, Inc.Bone matrix compositions having nanoscale textured surfaces

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2738299A (en)*1998-03-101999-09-27Imperial College Of Science, Technology And MedicineSolution
RU2218913C2 (en)*2001-01-242003-12-20Государственный научно-исследовательский институт особо чистых биопрепаратовInterferon preparation

Cited By (23)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7662185B2 (en)1999-12-302010-02-16Osteotech, Inc.Intervertebral implants
US8672980B2 (en)2000-10-202014-03-18Warsaw Orthopedic, Inc.Implant retaining device
US7780708B2 (en)2000-10-202010-08-24Osteotech, Inc.Implant retaining device
US7726002B2 (en)2001-12-052010-06-01Osteotech, Inc.Processes for making spinal intervertebral implant, interconnections for such implant
US9034358B2 (en)2003-12-312015-05-19Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US9415136B2 (en)2003-12-312016-08-16Warsaw Orthopedic, Inc.Osteoinductive demineralized cancellous bone
US8328876B2 (en)2003-12-312012-12-11Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US8734525B2 (en)2003-12-312014-05-27Warsaw Orthopedic, Inc.Osteoinductive demineralized cancellous bone
US8333985B2 (en)2004-01-272012-12-18Warsaw Orthopedic, Inc.Non-glycerol stabilized bone graft
US8911759B2 (en)2005-11-012014-12-16Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US8992965B2 (en)2005-11-012015-03-31Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US8372157B2 (en)2007-02-122013-02-12Warsaw Orthopedic, Inc.Joint revision implant
US8642061B2 (en)2007-06-152014-02-04Warsaw Orthopedic, Inc.Method of treating bone tissue
US8357384B2 (en)2007-06-152013-01-22Warsaw Orthopedic, Inc.Bone matrix compositions and methods
US9554920B2 (en)2007-06-152017-01-31Warsaw Orthopedic, Inc.Bone matrix compositions having nanoscale textured surfaces
US9333082B2 (en)2007-07-102016-05-10Warsaw Orthopedic, Inc.Delivery system attachment
US9358113B2 (en)2007-07-102016-06-07Warsaw Orthopedic, Inc.Delivery system
US9492278B2 (en)2007-07-102016-11-15Warsaw Orthopedic, Inc.Delivery system
US8435566B2 (en)2007-10-192013-05-07Warsaw Orthopedic, Inc.Demineralized bone matrix compositions and methods
US8202539B2 (en)2007-10-192012-06-19Warsaw Orthopedic, Inc.Demineralized bone matrix compositions and methods
US9011537B2 (en)2009-02-122015-04-21Warsaw Orthopedic, Inc.Delivery system cartridge
US9101475B2 (en)2009-02-122015-08-11Warsaw Orthopedic, Inc.Segmented delivery system
US9220598B2 (en)2009-02-122015-12-29Warsaw Orthopedic, Inc.Delivery systems, tools, and methods of use

Also Published As

Publication numberPublication date
DE2253086B2 (en)1978-06-15
DE2253086A1 (en)1974-05-09

Similar Documents

PublicationPublication DateTitle
DE2253086C3 (en) Preserving solutions for infusion and for storage of tissues and tissue parts
CaldwellStudies on the internal pH of large muscle and nerve fibres
DE69308673T2 (en) Solution for use in organ transplantation
DE3784916T4 (en) GLUCOSE-FREE MEDIA FOR THE STORAGE OF BLOOD PLATES.
DE68921945T2 (en) Method for lyophilizing cells Lyophilizing media and method for restoring lyophilized cells.
CH624579A5 (en)
DE2655801A1 (en) METHOD FOR PRODUCING A MASS OF LOADED CELLS SUSPENDED IN A PHYSIOLOGICAL SOLUTION
EP0040799A2 (en)Stabilized thrombin preparation
DE69811220T2 (en) COMPOSITIONS FOR THE PRESERVATION OF LIVING BIOLOGICAL MATERIALS AND METHOD FOR THEIR USE
DE4331711C2 (en) Solution for perfusion, preservation and re-perfusion of organs
Whittembury et al.Electrical potential difference measurements in perfused single proximal tubules of Necturus kidney
CH657502A5 (en) METHOD FOR PRODUCING FLEXIBLE, SUSTAINABLY MADE NON-PRESERVED AND PRESERVED BIOLOGICAL MATERIALS.
Hausmann et al.Iron storage in macrophages and endothelial cells. Histochemistry, ultrastructure, and clinical significance
DE2258519A1 (en) PROCESS FOR OBTAINING A COSMETOLOGICAL PRODUCT
CN104542571B (en)A kind of preserving corpse samples liquid
EP0012272B1 (en)Protecting solution for heart and kidneys and process for its manufacture
DE69625254T2 (en) COMPOSITIONS AND METHODS FOR PRESERVING LIVING TISSUES
Gayton et al.The location of chloride in single striated muscle fibers of the giant barnacle
Feuvray et al.Effect of short dimethylsulfoxide perfusions on ultrastructure of the isolated rat heart
HaynesThe action of salts and non-electrolytes upon buffer solutions and amphoteric electrolytes and the relation of these effects to the permeability of the cell
PonderThe permeability of human red cells to cations after treatment with resorcinol, n-butyl alcohol, and similar lysins
Seyama et al.The effect of high sodium concentration on the action potential of the skate heart
DE710410C (en) Process for increasing the coagulability of animal blood
StantonThe selective absorption of potassium by animal cells: iii. the effect of hydrogen ion concentration upon the retention of potassium
ScholanderOxygen Dissociation Curves in Fish Blood1

Legal Events

DateCodeTitleDescription
OGANew person/name/address of the applicant
C3Grant after two publication steps (3rd publication)
8339Ceased/non-payment of the annual fee

[8]ページ先頭

©2009-2025 Movatter.jp